Torrent Pharmaceuticals
High-margin, brand-led franchise dominated by India chronic therapies (cardiac, CNS, GI) plus Brazil and Germany; consistent M&A integrator (Unichem, Curatio, JB Pharma bid).
A full research profile for one company — what it does, how its financials have trended, how the market values it, and a balanced bull/bear/base investment memo.
Scan the top row for the headline numbers, read the charts for trends, check the three gauge scores, then read the auto-generated memo at the bottom. Sources for every figure are linked at the very bottom.
- EBITDA
- — Earnings before interest, tax, depreciation & amortisation — a proxy for operating cash profit.
- PAT
- — Profit After Tax — the bottom-line net profit.
- FCF
- — Free Cash Flow — cash left after running the business and capital spending.
- ANDA
- — Abbreviated New Drug Application — the US FDA filing to sell a generic drug.
Revenue
₹ crore · FY
EBITDA
₹ crore · FY
Margins
EBITDA & PAT margin %
R&D Spend
₹ crore · FY
Free Cash Flow
₹ crore · FY
Revenue Mix
By geography / segment
Quality Score
Growth Score
Regulatory Risk
Snapshot
Business Model
How the company makes money
India branded chronic-led franchise + Brazil/Germany branded generics; low US exposure.
India chronic + brand acquisitions + margin expansion
Premium valuation & leverage from M&A
Peer Group
Click to compare
| Peer | Rev CAGR | EBITDA% | ROCE | P/E |
|---|---|---|---|---|
| Torrent Pharmaceuticals | 25% | 32% | 27% | 68x |
| Mankind Pharma | 0% | 25% | 13.5% | 49x |
| Alkem Laboratories | 11% | 19% | 21.2% | 26x |
| Eris Lifesciences | 14% | 35% | 14% | 31x |
| J.B. Chemicals & Pharmaceuticals | 23% | 26% | 26% | 49x |
| Cipla | 7% | 26% | 23% | 29x |
Investment Memo
Auto-generated from the data layer — illustrative, not advice
- • India chronic + brand acquisitions + margin expansion underpins a 25% 5Y revenue CAGR.
- • Premium 32% EBITDA margin with 27% ROCE signals durable economics.
- • Capacity already in place to support the next growth phase.
- • Premium valuation & leverage from M&A.
- • Pricing/NLEM exposure on the domestic book can cap realisation.
- • Valuation at 68x P/E prices in continued execution — little margin for error.
Torrent Pharmaceuticals screens as a high-quality domestic formulations franchise. With revenue of ₹11.5K Cr growing ~25% and 32% EBITDA margins, the base case is steady compounding driven by india chronic + brand acquisitions + margin expansion, while watching premium valuation & leverage from m&a.
Trades at 68x P/E, 42.0x EV/EBITDA and 17.9x P/B. A premium to the sector — justified only if growth and returns hold.
- 1 India IPM outperformance & chronic mix
- 2 Gross-margin trajectory & new-launch contribution
- 3 R&D productivity (filings/approvals per ₹ of R&D)
- 4 Capital allocation — capex payback & M&A discipline
Mix approx from broker notes (India ~55%, Brazil/Germany ~35%, US ~10%). Premium branded valuation.